The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.

ABSTRACT:

Purpose

The current study was carried out to compare the effectiveness and safety of different ALK inhibitors in treating ALK+ NSCLC.

Methods

Progression-free survival (PFS), disease control rate (DCR), overall response rate (ORR), and intracranial ORR and DCR have been aggregated to appraise the effectiveness of each ALKi. The discontinuation rate due to adverse events (AEs) was pooled to evaluate their safety. Bayesian network meta-analyses were used to compare the ORR, DCR, PFS, and discontinuation rate of patients treated with alectinib, ceritinib, crizotinib, and chemotherapy.

Results

Compared with chemotherapy, ALK inhibitors significantly prolonged PFS [hazard ratio (HR) and 95% confidence interval (CI): alectinib, 0.50 (0.43-0.58); ceritinib, 0.75 (0.69-0.83);

SUBMITTER: Fan J 

PROVIDER: S-EPMC6198244 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature